As a genetics researcher, Britt Drögemöller is particularly passionate about understanding how genetic variation contributes to human disease and the treatment thereof. Britt completed her PhD in human genetics at Stellenbosch University, South Africa, after which she moved to Vancouver to take up a position as a postdoctoral research fellow at the University of British Columbia. Her current research focuses on performing genome-wide scans to identify genetic variants that are associated with adverse drug reactions caused by chemotherapy. The identification of these variants allows for the ability to predict which patients are at risk of experiencing adverse drug reactions before therapy begins so that novel treatment strategies can be considered in these patients.
"CIHR Drug Safety and Effectiveness Cross‐Disciplinary Training (DSECT) Program 2017-2018." Drögemöller B.
"Child and Family Research Institute Hoffmeister fellowship 2015-2016." Drögemöller B.
"L'Oréal-UNESCO for Women in Science in Sub-Saharan Africa Fellowship 2012." Drögemöller B.
"South African National Research Foundation Innovation Doctoral Scholarship 2010-2013." Drögemöller B.
"Harry Crossley Foundation Bursary 2008-2009." Drögemöller B.
"Genetic variation in SLC16A5 confers protection from cisplatin-induced ototoxicity in adult testicular cancer patients." Drögemöller B. American Society of Human Genetics. Vancouver, BC. October 18–22, 2016.
"Genetic variation in SLC16A5 confers protection from cisplatin-induced ototoxicity in adult testicular cancer patients." Drögemöller B. Canadian Society of Pharmacology and Therapeutics. Vancouver, BC. September 18–20, 2016.
"Genome-wide association study of L-asparaginase-induced pancreatitis in children." Drögemöller B. The 13th International Congress for Human Genetics. Kyoto, Japan. April 3–7, 2016.
"Genome-wide association study of L-asparaginase-induced pancreatitis in children." Drögemöller B. International Society of Paediatric Oncology Congress. Cape Town, South Africa. October 8–11, 2015.
"The use of exome sequencing for antipsychotic pharmacogenomic application in South African schizophrenia patients." Drögemöller B. Biological Psychiatry Congress. Wild Coast Sun, South Africa. August 29–September 1, 2013.